Показано 0 из 0
Дата |
---|
16.05.2024 |
15.05.2024 |
14.05.2024 |
13.05.2024 |
10.05.2024 |
09.05.2024 |
08.05.2024 |
07.05.2024 |
06.05.2024 |
03.05.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
2.93
|
3.05
|
2.93
|
2.83
|
3.05
|
2.96
|
|
|
167 478.93
|
434.00
|
2.75
|
3.11
|
2.9186
|
2.74
|
3.04
|
2.83
|
|
|
127 002.72
|
361.00
|
2.31
|
3.06
|
3.01
|
2.77
|
3.0743
|
2.97
|
|
|
110 197.99
|
319.00
|
2.90
|
3.10
|
2.85
|
2.80
|
2.99
|
2.99
|
|
|
55 745.43
|
266.00
|
2.31
|
2.87
|
2.69
|
2.64
|
2.85
|
2.85
|
|
|
72 699.54
|
214.00
|
2.72
|
2.87
|
2.81
|
2.78
|
2.87
|
2.82
|
|
|
14 827.08
|
131.00
|
2.65
|
2.87
|
2.6754
|
2.6754
|
2.83
|
2.78
|
|
|
125 660.63
|
293.00
|
2.34
|
2.77
|
2.70
|
2.61
|
2.77
|
2.64
|
|
|
39 548.99
|
212.00
|
2.38
|
2.87
|
2.7898
|
2.3335
|
2.7898
|
2.60
|
|
|
238 160.56
|
654.00
|
2.56
|
2.90
|
2.85
|
2.59
|
2.9872
|
2.60
|
|
|
122 558.21
|
404.00
|
First Wave BioPharma Inc (formerly AzurRx BioPharma Inc) is a developer of targeted, non-systemic therapies intended for gastrointestinal diseases. The company's clinical-stage programs are built around its two proprietary technologies an oral small molecule with anti-viral and anti-inflammatory properties and a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, enabling patients suffering from gastrointestinal infections, ulcerative proctitis and other colitis and diarrhea diseases to receive proper treatment.